📋 Key Information Summary
- Wilson disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene on chromosome 13, leading to impaired biliary copper excretion and toxic copper accumulation in liver, brain, cornea, and kidneys.
- Australian prevalence approximately 1 in 30,000; carrier frequency ~1 in 90. Higher consanguinity rates in some Aboriginal and Torres Strait Islander communities may increase local prevalence.
- Diagnosis uses the Leipzig (Ferenci) scoring system — a composite score incorporating ceruloplasmin, urinary copper, Kayser-Fleischer rings, liver copper, and ATP7B genotyping. Score ≥4 is diagnostic.
- Key diagnostic tests: serum ceruloplasmin <0.2 g/L, 24-hour urinary copper >1.6 µmol/24h (baseline), >25 µmol/24h after penicillamine challenge in children, and liver biopsy copper >250 µg/g dry weight.
- Kayser-Fleischer rings — golden-brown corneal deposits seen on slit-lamp examination — present in ~95% of neurological Wilson disease but only ~50% of hepatic presentations.
- First-line treatment: D-penicillamine (with concurrent pyridoxine 25 mg/day) 1–1.5 g/day in divided doses; risk of paradoxical neurological worsening in first weeks of therapy.
- Second-line chelator: trientine (triethylenetetramine dihydrochloride) 750–1500 mg/day, better tolerated with fewer adverse effects; pregnancy data more limited than penicillamine.
- Zinc acetate 150 mg elemental zinc/day (in 3 divided doses) as maintenance therapy or first-line in paucisymptomatic patients; acts by inducing intestinal metallothionein to block copper absorption.
- All patients require lifelong low-copper diet — avoid organ meats, shellfish, nuts (especially cashews), mushrooms, and chocolate.
- Wilsonian acute liver failure (ALF) is a medical emergency: typically young women, Coombs-negative haemolytic anaemia, ALP:bilirubin ratio <4, AST:ALT ratio >2.2, low serum uric acid, and very high mortality without urgent liver transplant.
- King's College Wilson Index predicts need for transplant: score ≥11 (or bilirubin >300 µmol/L with INR >6.5) mandates urgent transplant listing.
- Monitoring: 24-hour urinary copper (target 3–8 µmol/day on chelation), LFTs, FBC, direct Coombs test, and neurological assessment regularly. Non-compliance risk is lifelong.
- ATSI populations face diagnostic delays due to limited specialist and slit-lamp access in remote communities; culturally appropriate genetic counselling and family screening are essential.
Introduction & Australian Epidemiology
Wilson disease (hepatolenticular degeneration) is an autosomal recessive disorder of copper homeostasis caused by biallelic pathogenic variants in the ATP7B gene (chromosome 13q14.3). The encoded copper-transporting ATPase is expressed predominantly in hepatocytes and is essential for incorporating copper into caeruloplasmin and for biliary copper excretion. Loss of ATP7B function results in toxic hepatic copper accumulation, spillover into the systemic circulation, and deposition in the basal ganglia, cornea, kidneys, and other tissues.
Australian Epidemiology
- Estimated prevalence: 1 in 30,000 live births; carrier frequency approximately 1 in 90 across most Australian populations.
- The disease is pan-ethnic but certain founder mutations may be enriched in specific communities. Over 800 ATP7B variants are catalogued; H1069Q (European) and R778L (East Asian) are the most common worldwide.
- In Aboriginal and Torres Strait Islander communities, higher rates of consanguinity in some regions may increase homozygosity for recessive conditions including Wilson disease, though population-level prevalence data are limited.
- Presentation age is typically 5–35 years (hepatic form earlier, neurological form later), but cases diagnosed in the sixth decade are well documented.
- The AIHW National Notifiable Diseases Surveillance System does not capture Wilson disease; true Australian incidence is inferred from tertiary centre registries and transplant data.
- Australian liver transplant registries report Wilson disease as an indication in approximately 3–5% of paediatric transplants and 1–2% of adult transplants annually.
Pathophysiology
Copper is absorbed in the proximal small intestine and transported to the liver bound to albumin and transcuprein. In healthy hepatocytes, ATP7B shuttles copper to the trans-Golgi network for incorporation into apocaeruloplasmin and, when copper is replete, trafficks to the canalicular membrane for biliary excretion (the major route of copper elimination). In Wilson disease, ATP7B dysfunction causes:
- Failure to secrete copper into bile → hepatic copper overload → oxidative damage, steatosis, hepatitis, fibrosis, cirrhosis.
- Failure to incorporate copper into apocaeruloplasmin → accelerated degradation of apocaeruloplasmin → low serum caeruloplasmin.
- Non-caeruloplasmin-bound copper spilling into plasma → deposition in brain (lenticular nucleus, putamen, caudate), cornea (Descemet membrane → Kayser-Fleischer rings), kidneys (proximal tubular damage → aminoaciduria, Fanconi-like syndrome), and red blood cells (acute haemolysis).
- Cerebral copper toxicity produces the characteristic neuropsychiatric manifestations: dystonia, dysarthria, tremor, psychiatric disturbance (depression, psychosis, behavioural change).
Late diagnosis is common: Median delay from symptom onset to diagnosis in Australian series is 6–18 months. Any unexplained liver disease, Coombs-negative haemolysis, or movement disorder in a patient aged 5–40 years should prompt Wilson disease screening.
Diagnosis
No single test is pathognomonic for Wilson disease. Diagnosis rests on a combination of clinical, biochemical, histological, and genetic findings, scored using the Leipzig (Ferenci) Scoring System. A cumulative score of ≥4 is considered diagnostic.
Leipzig (Ferenci) Scoring System
| Parameter | Finding | Score |
|---|---|---|
| Kayser-Fleischer rings | Present on slit-lamp (experienced observer) | 2 |
| Absent | 0 | |
| Present but examination not available | 1 | |
| Serum caeruloplasmin | <0.1 g/L | 2 |
| 0.1–0.2 g/L | 1 | |
| >0.2 g/L | 0 | |
| Coombs-negative haemolytic anaemia | Present | 1 |
| Absent | 0 | |
| 24-hour urinary copper (baseline) | Above normal (>1.6 µmol/24h or >100 µg/24h) | 1 |
| Normal but >1× ULN after D-penicillamine challenge* | 1 | |
| Normal | 0 | |
| Liver copper quantification (biopsy) | >250 µg/g dry weight (5 µmol/g) | 2 |
| 50–250 µg/g dry weight | 1 | |
| Normal (<50 µg/g dry weight) — stain negative | −1 | |
| Rhodamine-positive hepatocytes (histochemistry) | Positive | 1 |
| Negative | 0 | |
| ATP7B mutation analysis | Homozygous or compound heterozygous mutation | 4 |
| Heterozygous mutation (1 allele detected) | 1 | |
| No mutation detected | 0 |
Interpretation: Total score ≥4 = diagnosis established; 2–3 = diagnosis possible — further testing required (consider liver biopsy with copper quantification or genetic testing); ≤1 = diagnosis unlikely.
Key Diagnostic Investigations
Essential
Serum caeruloplasmin
Immunonephelometric assay. <0.2 g/L is suggestive; <0.1 g/L is highly suggestive. Low in ~90% of Wilson disease patients. Also low in protein-losing states, end-stage liver disease, and hereditary acaeruloplasminaemia (rare). MBS Item 66542 (Protein electrophoresis) or 66538 (caeruloplasmin immunoassay).
Essential
24-hour urinary copper excretion
Collect in acid-washed container. Baseline >1.6 µmol/24h (100 µg/24h) is abnormal. In children, post-penicillamine challenge ( 500 mg PO BD for 1 day with 24h urine collection ) yielding >25 µmol/24h (>1600 µg/24h) is highly predictive. MBS Item 66814 (Copper, urine).
Available
Kayser-Fleischer ring assessment — slit-lamp examination
Golden-brown granular deposits in Descemet membrane at the limbus. Present in ~95% of neurological Wilson disease, ~50% of hepatic-only presentations, ~35% of asymptomatic siblings. Requires experienced ophthalmologist. Not present in all confirmed Wilson disease (absence does not exclude diagnosis).
Specialist
Percutaneous liver biopsy with copper quantification
Tissue submitted for copper quantification by atomic absorption spectroscopy or ICP-MS. >250 µg/g dry weight (5 µmol/g) is diagnostic. Normal <50 µg/g. Also useful for staging hepatic fibrosis and assessing steatosis, hepatitis, Mallory bodies. Histochemistry (orcein, rhodamine, rubeanic acid) — rhodamine-positive hepatocytes scored in Leipzig system. Available at major Australian teaching hospitals and reference laboratories.
Available
ATP7B gene sequencing
Next-generation sequencing panel or targeted Sanger sequencing. Homozygous or compound heterozygous pathogenic variants = 4 points on Leipzig score. Essential for confirming diagnosis and enabling cascade family screening. Available through Australian clinical genetics services (e.g., Victorian Clinical Genetics Services, SA Pathology Genetics). Turnaround 4–8 weeks.
Available
Serum free (non-caeruloplasmin-bound) copper
Calculated as total serum copper minus caeruloplasmin-bound copper (3.15 × caeruloplasmin in g/L). Normally <1.6 µmol/L (10 µg/dL). Elevated in Wilson disease. Useful for monitoring treatment response but not included in Leipzig score. Can be spuriously low in acute hepatic failure.
Available
Direct Coombs test (DAT)
Essential when haemolysis is present. In Wilsonian haemolysis, DAT is negative (distinguishes from autoimmune haemolytic anaemia). MBS Item 65070 (Blood group serology).
Available
MR brain (T1/T2/FLAIR/SWI)
Not diagnostic per se but demonstrates characteristic hyperintensities in the basal ganglia (putamen, caudate, globus pallidus), thalamus, midbrain, and pons. "Face of the giant panda" sign in tegmentum is classic. SWI shows susceptibility artifact from copper/iron deposition. Useful in neurological presentations.
Diagnostic Approach by Clinical Presentation
Hepatic Presentation (typically age 5–20)
- Chronic hepatitis mimicking autoimmune hepatitis
- Steatohepatitis (non-alcoholic pattern)
- Cryptogenic cirrhosis
- Fulminant hepatic failure with haemolysis (see Acute Liver Failure section)
- Kayser-Fleischer rings may be absent (~50%)
Neuropsychiatric Presentation (typically age 15–35)
- Resting or wing-beating tremor
- Dystonia (risus sardonicus, dysarthria)
- Dysphagia, sialorrhoea
- Psychiatric: depression, anxiety, psychosis, behavioural change
- Kayser-Fleischer rings usually present (~95%)
Treatment
Treatment is lifelong and must be initiated as soon as the diagnosis is confirmed, regardless of symptoms. The goals of therapy are to remove accumulated copper, prevent further copper deposition, and manage symptoms. All patients require dietary modification, and most require pharmacological copper chelation or zinc therapy.
Penicillamine neurological worsening: Up to 20–50% of patients with neurological Wilson disease experience paradoxical worsening of neurological symptoms during the first 2–8 weeks of D-penicillamine therapy. Consider starting at a low dose (250 mg/day) with gradual uptitration, or using trientine as first-line in neurological presentations.
Copper Chelators
D-Penicillamine
Cuprimine® · Trolovol® · Penicillamine
Mechanism
Copper chelator — promotes urinary copper excretion; also induces metallothionein synthesis
Adult dose
Start 250–500 mg/day PO in 2–4 divided doses; titrate over 2–4 weeks to 750–1500 mg/day. Take 1 hour before or 2 hours after meals.
Paediatric dose
20 mg/kg/day PO (max 750–1000 mg/day) in 2–3 divided doses
Mandatory co-prescription
Pyridoxine (Vitamin B₆) 25 mg PO daily — penicillamine is a pyridoxine antagonist
Key adverse effects
Neurological worsening (early treatment), hypersensitivity (rash, fever, lymphadenopathy, proteinuria, SLE-like), bone marrow suppression, nephrotic syndrome, oral ulcers, elastosis perforans serpiginosa
Renal adjustment
Use with caution if eGFR <30; no specific dose table; monitor proteinuria closely
PBS status
✔ PBS General Benefit
Trientine (triethylenetetramine dihydrochloride)
Syprine® · Trientine · Cuprior®
Mechanism
Copper chelator — promotes urinary copper excretion; may also induce intestinal metallothionein
Adult dose
750–1500 mg/day PO in 2–3 divided doses, taken 1 hour before or 2 hours after meals
Paediatric dose
500–750 mg/day PO in 2–3 divided doses (adjust by weight)
Key advantages
Lower risk of neurological worsening compared to penicillamine; better tolerated overall; suitable first-line in neurological presentations and pregnancy
Key adverse effects
GI upset, sideroblastic anaemia (rare), lupus-like syndrome (very rare), iron deficiency (chelates iron — monitor ferritin)
Renal adjustment
Limited data; monitor renal function
PBS status
⚠️ PBS Authority Required — Specialist initiation required; contact PBS Authority line.
Zinc Therapy
Zinc acetate / zinc sulphate
Wilzin® · Zinc acetate · Zinc sulphate
Mechanism
Induces intestinal cell metallothionein → blocks dietary copper absorption; also induces hepatic metallothionein for intracellular copper sequestration
Adult dose
150 mg elemental zinc/day PO in 3 divided doses (50 mg TDS). Take 1 hour before or 2 hours after meals. Separate from meals containing phytate.
Paediatric dose (>5 years)
75 mg elemental zinc/day PO in 3 divided doses (25 mg TDS)
Indications
Maintenance therapy after initial chelation (2–5 years); first-line in asymptomatic/paucisymptomatic patients and presymptomatic siblings; adjunct to chelator; pregnancy
Key adverse effects
GI irritation (nausea, epigastric pain — take between meals), metallic taste, mild lipase/amylase elevation, copper deficiency with excess dosing
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit (zinc sulphate); Wilzin® may require Authority
Treatment Strategy
Initial Phase
Decoppering (first 1–2 years)
Chelator monotherapy (penicillamine or trientine). Titrate to target dose. Monitor 24h urinary copper monthly initially.
Setting: Specialist hepatology/GI outpatient
Transition Phase
Switch to maintenance (2–5 years)
When biochemical normalisation achieved (normal LFTs, urinary copper 3–8 µmol/day, serum free copper normal) — switch to zinc monotherapy or zinc + low-dose chelator.
Setting: Specialist + GP shared care
Maintenance Phase
Lifelong therapy
Zinc monotherapy in stable patients; continue chelator if significant ongoing copper load or neurological disease. Lifelong monitoring. Never stop treatment.
Setting: Annual specialist review + GP monitoring
Low-Copper Diet
Dietary copper restriction is an essential adjunct to pharmacotherapy in all Wilson disease patients.
⛔ Foods to Avoid (High Copper)
- Organ meats (liver, kidney) — very high copper
- Shellfish (oysters, crab, lobster, mussels)
- Nuts — especially cashews, Brazil nuts, sunflower seeds
- Chocolate and cocoa
- Mushrooms (dried especially)
- Soy products (tofu, soy milk)
- Dried fruits (prunes, figs)
- Multivitamins with copper
- Copper cookware; water from copper pipes (first morning flush)
✅ Foods Generally Safe
- Meat (muscle, not organ) — moderate copper
- Dairy products
- Eggs
- White bread, rice, pasta
- Most fruits and vegetables (except those listed to avoid)
- Tea and coffee (in moderation)
Monitoring Protocol
| Test | Frequency | Target / Interpretation |
|---|---|---|
| 24-hour urinary copper | Monthly × 6 months, then 3-monthly, then annually | On chelator: 3–8 µmol/day (200–500 µg/day). <2 µmol/day on chelator = non-compliance risk. On zinc: 0.5–1.5 µmol/day. |
| LFTs (ALT, AST, GGT, ALP, bilirubin, albumin) | Monthly initially → 3-monthly → annual | Normalisation within 6–12 months expected. Rising ALT may indicate non-compliance or inadequate therapy. |
| FBC, reticulocyte count | Monthly × 6 months (penicillamine), then 3-monthly | Penicillamine: watch for thrombocytopaenia, leukopaenia, sideroblastic anaemia (trientine). |
| Serum free copper | 3-monthly initially → annual | Target <1.6 µmol/L. Rising values suggest non-compliance or inadequate dose. |
| Urinalysis + urine protein | Monthly (penicillamine) → 3-monthly | Penicillamine nephrotoxicity: proteinuria >1 g/day warrants dose review. |
| Neurological examination | 3-monthly initially → 6-monthly | Objective assessment of tremor, dystonia, dysarthria. Document baseline before treatment. |
| Slit-lamp examination | Annual | KF rings may fade with effective therapy. Persistence suggests inadequate decoppering. |
Acute Liver Failure
Wilsonian acute liver failure (ALF) accounts for approximately 5–12% of all non-paracetamol ALF cases in Australian transplant centres. It represents the most immediately life-threatening presentation of Wilson disease and requires rapid recognition and urgent transplant assessment.
Medical emergency: Wilsonian ALF has near-100% mortality without liver transplantation. Early transfer to a liver transplant centre (e.g., Royal Prince Alfred Hospital Sydney, Austin Health Melbourne, Princess Alexandra Hospital Brisbane, Sir Charles Gairdner Hospital Perth, Flinders Medical Centre Adelaide) is mandatory when Wilsonian ALF is suspected.
Clinical Features of Wilsonian ALF
Wilsonian ALF has a distinctive biochemical and clinical profile that differs from other causes of ALF:
- Demographics: Typically young women (female: male ratio ~2:1), age 12–30 years (though can occur at any age).
- Coombs-negative haemolytic anaemia: Present in virtually all cases. Acute copper release from necrotic hepatocytes causes direct oxidative haemolysis. Reticulocytosis may be present. Direct Coombs (DAT) is negative.
- Very high bilirubin with disproportionately low ALP: The hallmark ratio — ALP (IU/L) / total bilirubin (mg/dL) <4 [or ALP:bilirubin (µmol/L) ratio <0.57]. This reflects the combination of haemolysis-driven hyperbilirubinaemia and falling hepatic synthetic production of ALP.
- AST > ALT: AST:ALT ratio >2.2 is characteristic. Both transaminases are typically elevated but rarely exceed 2000 IU/L (unlike paracetamol ALF).
- Low serum uric acid: Copper-induced proximal tubular dysfunction causes renal uric acid wasting. Hypouricaemia is a useful diagnostic clue.
- Low caeruloplasmin: Usually very low, but can be misleadingly normal due to acute-phase response.
- Kayser-Fleischer rings: Usually present in ALF (often absent in chronic hepatic presentations, but the acute decompensation usually occurs in patients who already have established copper deposition).
- Rapidly progressive: Jaundice → coagulopathy → hepatic encephalopathy → multi-organ failure within days to weeks.
Diagnostic Clue: The ALP:Bilirubin Ratio
ALP:bilirubin ratio <4 (using conventional units: ALP in IU/L, bilirubin in mg/dL) — or equivalently ALP (IU/L) : bilirubin (µmol/L) <0.57 — in the setting of Coombs-negative haemolysis should trigger immediate Wilson disease workup. This ratio has a sensitivity >90% for Wilsonian ALF.
King's College Wilson Index (Modified)
The King's College Criteria for Wilsonian ALF use a scoring system to predict the need for urgent liver transplantation. The score is calculated at presentation:
| Parameter | Score |
|---|---|
| Serum bilirubin (µmol/L) | Bilirubin / 100 (= points) |
| AST (IU/L) | AST / 100 (= points) |
| INR | INR × 100 (= points) |
| WBC (×10⁹/L) | WBC × 10 (= points) |
| ALP:bilirubin ratio (conventional units) | Ratio <4 = additional predictor |
Transplant indicated if: King's Wilson Index score ≥11, OR bilirubin >300 µmol/L with INR >6.5, OR any two of: bilirubin >200 µmol/L, INR >4, serum creatinine >200 µmol/L, AST >400 IU/L. List for transplant immediately; do not wait for complete biochemical results.
Immediate Management of Wilsonian ALF
1
Transfer to Transplant Centre
Arrange urgent retrieval via state/territory organ donation and transplantation service. Activate liver transplant waiting list. Intubate and ventilate if encephalopathy ≥Grade II.
2
Plasmapheresis / Plasma Exchange
Large-volume plasmapheresis (daily) removes free copper from the circulation and replaces coagulation factors. Continue until transplant or recovery. Also provides temporary stabilisation.
3
Haemodialysis / CVVHDF
Continuous veno-venous haemodiafiltration in combination with plasmapheresis enhances copper removal. Treat concurrent renal failure.
4
Chelation
Intravenous D-penicillamine is not available in Australia; use oral penicillamine 250–500 mg via NG tube if tolerated, or trientine. However, chelation alone is insufficient in ALF — transplant remains definitive.
5
Supportive ICU Care
Manage coagulopathy (FFP, cryoprecipitate — avoid excess volume), hepatic enchaephalopathy (lactulose, rifaximin), renal support, infection prophylaxis, electrolyte correction (watch hypokalaemia, hypomagnesaemia).
6
Liver Transplantation
The only definitive treatment for Wilsonian ALF. Outcomes are excellent with 1-year survival >85%. Pre-emptive listing is recommended as soon as King's Wilson Index threshold is met — waiting for confirmation wastes critical time.
Differential Diagnosis of ALF with Haemolysis
| Condition | Key Distinguishing Feature |
|---|---|
| Wilsonian ALF | Coombs-negative haemolysis, ALP:bilirubin <4, low uric acid, KF rings, AST:ALT >2.2 |
| Autoimmune hepatitis flare | Positive autoantibodies (ANA, ASMA, anti-LKM-1), elevated IgG, Coombs may be positive |
| Haemophagocytic lymphohistiocytosis | Very high ferritin, cytopenias, hypertriglyceridaemia, low fibrinogen, haemophagocytes on biopsy |
| Paracetamol toxicity | Very high AST/ALT (>3000), paracetamol level, history, no haemolysis |
| Budd-Chiari syndrome | Doppler US showing hepatic vein thrombosis, hepatomegaly, ascites |
| Pregnancy-related ALF (AFLP, HELLP) | Pregnancy setting, HELLP = haemolysis, elevated LFTs, low platelets; delivery is treatment |
Special Populations
Pregnancy
Penicillamine
Teratogenic at high doses (cutis laxa, connective tissue defects). If used, minimise dose (500–750 mg/day) especially in first trimester. Some specialists prefer trientine.
Trientine
Limited human data but generally preferred over high-dose penicillamine in pregnancy. Case series suggest safety. Continue lowest effective dose.
Zinc
Considered safest option in pregnancy. Can be used as monotherapy in well-controlled patients or as adjunct. No teratogenic effects reported.
General
Never discontinue treatment in pregnancy — risk of acute hepatic decompensation. Monitor LFTs, urinary copper every trimester. Genetic counselling recommended for partner testing.
Paediatric
Diagnosis
Penicillamine challenge test more useful in children (250 mg BD for 1 day, 24h urine collection; >25 µmol/24h diagnostic). KF rings often absent in hepatic presentations <10 years.
Treatment
Penicillamine 20 mg/kg/day (max 750 mg) or trientine 500–750 mg/day with pyridoxine. Zinc 75 mg elemental/day for children >5 years. Family screening of all siblings essential.
Elderly
Presentation
Late-onset Wilson disease (>40 years) is well described. May present as psychiatric disorder or mild tremor mimicking essential tremor. Maintain a high index of suspicion.
Treatment
Penicillamine may be poorly tolerated (bone marrow suppression risk increases with age). Trientine or zinc may be preferred. Monitor renal function closely.
Renal Impairment
Penicillamine
Caution if eGFR <30. Penicillamine itself can cause nephrotic syndrome and proteinuria. Monitor urinalysis closely. Consider trientine or zinc as alternatives.
Zinc
No renal dose adjustment required. May be preferred in significant renal impairment.
Dialysis
Penicillamine is dialysable — dose after dialysis. CVVHDF combined with plasmapheresis is used in Wilsonian ALF with renal failure.
Hepatic Impairment
General
Most Wilson disease patients have some degree of hepatic impairment. Drug metabolism of penicillamine and trientine is not hepatically dependent. Cirrhotic patients require variceal surveillance and HCC screening (6-monthly AFP + ultrasound) per Australian guidelines.
Acute on chronic
Acute hepatic decompensation in known Wilson disease may herald transition to ALF. Urgent reassessment with King's Wilson Index. Transplant listing threshold is lower.
Immunocompromised
Penicillamine
Causes immunosuppression (T-cell suppression). Use with caution in already immunocompromised patients. Monitor FBC closely for leukopaenia and thrombocytopaenia.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Wilson disease affects Aboriginal and Torres Strait Islander peoples. While population-level prevalence data are limited, the clinical impact is amplified by diagnostic delays, barriers to specialist access, and the need for lifelong treatment adherence in communities with competing health priorities.
📚 References
- 1. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671–685. doi:10.1016/j.jhep.2011.11.007
- 2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024
- 3. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139–142. doi:10.1034/j.1600-0676.2003.00824.x
- 4. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089–2111. doi:10.1002/hep.22261
- 5. Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017;21(4):755–767. doi:10.1016/j.cld.2017.06.011
- 6. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's College scores for liver transplantation. Liver Transpl. 2005;11(4):441–448. doi:10.1002/lt.20352
- 7. Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. doi:10.1038/s41572-018-0018-3
- 8. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet. 2007;369(9559):397–408. doi:10.1016/S0140-6736(07)60196-2
- 9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework. Canberra: AIHW; 2023. Available from: https://www.aihw.gov.au
- 10. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 10th edn. East Melbourne: RACGP; 2023.
- 11. Bruha R, Marecek Z, Pospisilova L, et al. Long-term follow-up of Wilson disease patients: a 25-year experience. QJM. 2021;114(12):851–857. doi:10.1093/qjmed/hcab086
- 12. Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11(8):1028–1035. doi:10.1016/j.cgh.2013.03.017
- 13. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132(4):264–278. doi:10.1016/S0022-2143(98)90039-7
- 14. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd edn. Sydney: ACSQHC; 2021.
- 15. RHDAustralia. Recommendations for Aboriginal and Torres Strait Islander peoples. Darwin: RHDAustralia; 2022. Available from: https://www.rhdaustralia.org.au